Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 15th Annual Needham Virtual Technology & Media Conference on Wednesday, May 20, at 10:00 a.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day.
This year’s conference will provide shareholders and investors the opportunity to see presentations from more than 150 leading public and private companies in the Technology and Media sectors in a structured and user-friendly virtual setting. For more information about the conference or to schedule a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at [email protected].
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Follow us on Twitter | LinkedIn | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005106/en/
Simulations Plus Aktie
Positive Tendenz für Simulations Plus mit mehreren Buy- und keiner Sell-Einschätzung.
Eine deutliche Steigerung um mehr als 20% ist für Simulations Plus mit einem Kursziel von 51 € gegenüber 34.0 € zu erwarten.